MDV3100

enzalutamide · Astellas Pharma Europe B.V.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for MDV3100, covering 2012-10-30 to 2019-10-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer [Phase 1]